英派斯(002899.SZ):擬斥1000萬元參投體育消費股權投資基金
格隆匯12月24日丨英派斯(002899.SZ)宣佈,為進一步佈局體育健康產業,尋求優化公司產業鏈的投資機會,提升核心競爭力和市場影響力,公司擬與水木聯合(北京)投資管理有限公司(簡稱“水木聯合”)及華人恆嘉科技有限公司(簡稱“華人恆嘉”)共同發起設立“水木聯合體育消費股權投資基金(有限合夥)”(具體名稱以工商部門核准為準)。
公司與相關方已於2020年12月24日簽訂《水木聯合體育消費股權投資基金(有限合夥)之合夥協議》。截至該協議簽署之日,該基金認繳出資規模為人民幣3100萬元,其中公司作為有限合夥人認繳出資人民幣1000萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.